About: Corneal xenotransplantation: Where are we standing?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Corneal xenotransplantation: Where are we standing? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Corneal xenotransplantation: Where are we standing?
Creator	Choi, Jin Kim, M Choi, H Yoon, C Choi, Hyuk Kim, Mee Yoon, Chang
source	Elsevier; Medline; PMC
abstract	The search for alternatives to allotransplants is driven by the shortage of corneal donors and is demanding because of the limitations of the alternatives. Indeed, current progress in genetically engineered (GE) pigs, the introduction of gene-editing technology by clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and advanced immunosuppressants have made xenotransplantation a possible option for a human trial. Porcine corneal xenotransplantation is considered applicable because the eye is regarded as an immune-privileged site. Furthermore, recent non-human primate studies have shown long-term survival of porcine xenotransplants in keratoplasty. Herein, corneal immune privilege is briefly introduced, and xenogeneic reactions are compared with allogeneic reactions in corneal transplantation. This review describes the current knowledge on special issues of xenotransplantation, xenogeneic rejection mechanisms, current immunosuppressive regimens of corneal xenotransplantation, preclinical efficacy and safety data of corneal xenotransplantation, and updates of the regulatory framework to conduct a clinical trial on corneal xenotransplantation. We also discuss barriers that might prevent xenotransplantation from becoming common practice, such as ethical dilemmas, public concerns on xenotransplantation, and the possible risk of xenozoonosis. Given that the legal definition of decellularized porcine cornea (DPC) lies somewhere between a medical device and a xenotransplant, the preclinical efficacy and clinical trial data using DPC are included. The review finally provides perspectives on the current standpoint of corneal xenotransplantation in the fields of regenerative medicine.
has issue date	2020-08-02(xsd:dateTime)
bibo:doi	10.1016/j.preteyeres.2020.100876
bibo:pmid	32755676
has license	no-cc
sha1sum (hex)	eaf3cdb0470945492abbd750d0cbba52ee9900d4
schema:url	https://doi.org/10.1016/j.preteyeres.2020.100876
resource representing a document's title	Corneal xenotransplantation: Where are we standing?
has PubMed Central identifier	PMC7396149
has PubMed identifier	32755676
schema:publication	Prog Retin Eye Res
resource representing a document's body	covid:eaf3cdb0470945492abbd750d0cbba52ee9900d4#body_text
is schema:about of	named entity 'xenotransplantation' named entity 'allotransplants' named entity 'liver' named entity 'DNase' named entity 'screening tests' named entity 'mentally ill' named entity 'innate immune' named entity 'Niederkorn' named entity 'cytotoxicity' named entity 'porcine' named entity 'CD8 +' named entity 'biologic agents' named entity 'xenotransplantation' named entity 'CD4 +' named entity 'hyperacute rejection' named entity 'thrombotic microangiopathy' named entity 'Sweden' named entity 'informed consent' named entity 'keratoplasty' named entity 'humoral' named entity 'organ' named entity 'CD25' named entity 'xenotransplants' named entity 'steroid' named entity 'T-cell' named entity 'CSs' named entity 'minipig' named entity 'miniature pig' named entity 'athymic' named entity 'steroid' named entity 'PERV' named entity 'Chimpanzee' named entity 'maintenance therapy' named entity 'intravenously' named entity 'Xenogeneic' named entity 'clinical trial' named entity 'CDC' named entity 'seronegative' named entity 'xenotransplantation' named entity 'porcine' named entity 'tacrolimus' named entity 'IP-10' named entity 'xenotransplants' named entity 'lymphoproliferative disorder' named entity 'xenotransplantation' named entity 'wild-type' named entity 'anti-CD20' named entity 'immunosuppressive' named entity '5.0' named entity 'PKP' named entity 'kidney' named entity 'baboon' named entity 'Ericsson' named entity 'humidity' named entity 'long-term' named entity 'allotransplantation' named entity 'interferon gamma' named entity 'CD40' named entity 'Riau' named entity 'mAb' named entity 'long-term' named entity 'rituximab' named entity 'neutrophils' named entity 'Nellore' named entity 'therapeutic target' named entity 'Leonard Bailey' named entity 'immune-privileged' named entity 'CD4 +' named entity 'clinical trials' named entity 'IVIG' named entity 'xenotransplantation' named entity 'Kidney' named entity 'complement' named entity 'desensitization' named entity 'pig'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software